Array Biopharma INC
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$2.7Mgeneral payments (2019-2025)
$42Kresearch payments (2019-2025)
8,897clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Braftovi $981K associated (2023-2025)
- Mektovi $514K associated (2023-2025)
- Lorbrena $313K associated (2023-2025)
- Tukysa $137K associated (2023-2025)
- Xalkori $134K associated (2023-2025)
- Paxlovid $7,566 associated (2023-2025)
- Comirnaty $6,666 associated (2023-2025)
- Xtandi $2,791 associated (2023-2025)
- Ibrance $2,342 associated (2023-2025)
- Talzenna $2,033 associated (2023-2025)
- Inlyta $1,340 associated (2023-2025)
- Bosulif $839 associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Sam Teichman | Oakland, CA | Cardiovascular Disease | $149,896.85 |
| Sarmen Sarkissian | Mission Hills, CA | Hematology & Oncology | $62,623.09 |
| Sunandana Chandra | Chicago, IL | Medical Oncology | $58,805.56 |
| Sajeve Thomas | Orlando, FL | Hematology & Oncology | $52,076.21 |
| Ryan Carr | Shelbyville, TN | Hematology & Oncology | $51,919.28 |
| Omid Hamid | Santa Monica, CA | Hematology & Oncology | $51,904.30 |
| John Sarantopoulos | San Antonio, TX | Medical Oncology | $47,099.30 |
| Robert Conry | Birmingham, AL | Hematology & Oncology | $37,315.62 |
| Maen Abdelrahim | Houston, TX | Medical Oncology | $32,998.92 |
| Ruby Kochhar | Hampton, VA | Hematology & Oncology | $29,214.07 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.